Senseonics Holdings, Inc. Common Stock’s (SENS) Buy Rating Reiterated at TD Cowen

TD Cowen reaffirmed their buy rating on shares of Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $15.00 price objective on the stock.

Other analysts have also recently issued reports about the company. Weiss Ratings cut Senseonics Holdings, Inc. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, October 22nd. Barclays initiated coverage on Senseonics Holdings, Inc. Common Stock in a report on Wednesday, October 7th. They set an “equal weight” rating and a $10.00 target price on the stock. Mizuho dropped their price target on Senseonics Holdings, Inc. Common Stock from $20.00 to $18.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 15th. Finally, Wall Street Zen raised Senseonics Holdings, Inc. Common Stock from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Senseonics Holdings, Inc. Common Stock currently has a consensus rating of “Hold” and a consensus target price of $13.00.

Senseonics Holdings, Inc. Common Stock Stock Up 4.4%

Shares of SENS stock opened at $9.75 on Tuesday. Senseonics Holdings, Inc. Common Stock has a 52-week low of $4.79 and a 52-week high of $10.64. The firm’s 50-day moving average is $9.17 and its 200-day moving average is $7.19. The company has a quick ratio of 6.40, a current ratio of 6.74 and a debt-to-equity ratio of 0.62.

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.08). The business had revenue of $14.48 million for the quarter. Senseonics Holdings, Inc. Common Stock had a negative return on equity of 165.80% and a negative net margin of 225.09%. As a group, equities research analysts forecast that Senseonics Holdings, Inc. Common Stock will post -2.31 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Douglas Roeder purchased 13,953 shares of Senseonics Holdings, Inc. Common Stock stock in a transaction that occurred on Wednesday, August 19th. The stock was acquired at an average cost of $8.98 per share, for a total transaction of $125,297.94. Following the purchase, the director directly owned 171,191 shares of the company’s stock, valued at $1,537,295.18. This trade represents a 8.87% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 4.70% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in SENS. Traynor Capital Management Inc. bought a new position in Senseonics Holdings, Inc. Common Stock during the third quarter worth about $152,000. State of Wyoming raised its stake in Senseonics Holdings, Inc. Common Stock by 27.2% in the 3rd quarter. State of Wyoming now owns 14,940 shares of the company’s stock worth $152,000 after purchasing an additional 3,199 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new stake in Senseonics Holdings, Inc. Common Stock in the 2nd quarter worth about $36,000. Readystate Asset Management LP acquired a new stake in Senseonics Holdings, Inc. Common Stock in the 2nd quarter worth about $574,000. Finally, Penn Capital Management Company LLC bought a new stake in Senseonics Holdings, Inc. Common Stock in the 2nd quarter valued at about $535,000. Institutional investors own 12.36% of the company’s stock.

About Senseonics Holdings, Inc. Common Stock

Senseonics Holdings, Inc is a medical technology company focused on developing and commercializing long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes. Its CGM technology is designed to measure glucose levels continuously through a small sensor inserted under the skin, with readings transmitted to an external smart transmitter and mobile application.

The company’s primary product is the Eversense CGM system. Unlike many conventional CGM systems that use an externally worn sensor, Eversense uses an implantable sensor and a removable, rechargeable transmitter worn over the sensor site.